相关实验视频

Updated: May 31, 2025

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

脂质核心-基托外混合纳米颗粒用于提高 sorafenib 口服生物可用性

Najam Us Sahar¹, Maleeha Gul¹, Ho-Ik Choi²

¹Riphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad 44000, Pakistan.

International journal of biological macromolecules

|January 23, 2025

概括

这项研究开发了新的脂质纳米颗粒,以增强索拉费尼布 (SRF) 的口服吸收. 桑涂层的纳米颗粒显著提高了SRF的生物可用性,克服了可溶性问题,以获得更好的治疗结果.

科学领域:

纳米技术纳米技术
制药科学制药科学
药物运输药物运输药物运输

背景情况:

索拉菲尼布 (SRF) 的有限水溶性阻碍了口服生物可用性,导致效果不佳.
开发先进的药物输送系统对于克服SRF的可溶性挑战至关重要.

研究的目的:

开发和表征索拉费尼布载入的固体脂质纳米粒子 (SRF-SLNs) 和脂质核心-基托外混合纳米粒子 (CS-SRF-SLNs).
评估这些纳米颗粒在改善SRF口服吸收和生物可用性的潜力.

主要方法:

准备SRF-SLN时使用了醇核心和表面活性剂稳定剂.
应用了奇托涂层来创建CS-SRF-SLNs.
进行了颗粒大小,PDI,泽塔潜力,封装效率,DSC,PXRD,体外释放和体外药理动力学研究.

主要成果:

无论是SRF-SLN还是CS-SRF-SLN,都表现出理想的物理化学特性 (小尺寸,低PDI,高封装效率).
CS-SRF-SLNs显示持续的药物释放和改善的水溶性.
与SRF-SLN和SRF分散相比,通过口服给老鼠的SRF生物可用性与CS-SRF-SLN显著增加.

结论:

CS-SRF-SLNs在口服索拉费尼布的输送方面优于SRF-SLNs.
这些混合纳米粒子有效地解决了SRF的可溶性限制,改善了其药理动力学特征和治疗潜力.

关键词:

脂质核心-奇托桑外混合纳米颗粒较差的水溶性较差的水溶性索拉费尼布 (Sorafenib) 是一种

更多相关视频

Preparation and Characterization of Nanoliposomes for the Entrapment of Bioactive Hydrophilic Globular Proteins

Preparation and Characterization of Nanoliposomes for the Entrapment of Bioactive Hydrophilic Globular Proteins

Published on: August 31, 2019

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

相关概念视频

Factors Affecting Dissolution: Particle Size and Effective Surface Area

Factors Affecting Dissolution: Particle Size and Effective Surface Area

Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...

Factors Affecting Dissolution: Drug pKa, Lipophilicity and GI pH

Factors Affecting Dissolution: Drug pKa, Lipophilicity and GI pH

Drug absorption within the gastrointestinal (GI) tract is a complex process influenced by several critical factors, including the site pH, the drug's dissociation constant (pKa), and the drug's lipophilicity. The GI tract exhibits a pH gradient, with an acidic environment in the stomach and a more alkaline environment in the small intestine. This pH variation directly affects the ionization state of drugs.
A drug's pKa and the pH of the gastrointestinal (GI) tract play crucial roles...

Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry

Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry

Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...